DNAJC5 and malaria: However, in a disappointing earlier prime/boost study in 18 adults, boosting a RTS,S/adjuvant formulation with a MVA construct expressing the P. falciparum CSP elicited enhanced immune responses but not improved protection against an experimental malaria challenge [17].